The approval of Aricept fifteen years ago was the last time there was anything new to treat the symptoms of Alzheimer’s disease. This lack of research and drug development is unnerving to patients and practitioners alike, with this lethal disease affecting 5.4 million Americans. On June 13, 2013 the BCC posted an alarming research report,[…]
Treatments Available for Surge of Alzheimer’s Cases
Anti-Alzheimer's, Antidimentia, Drug Research & Development API Tags: 120014-06-441100-52-1acetylcholineAlzheimers diseaseDonepezilMemantine Jul 02, 2013
Alzheimers Disease Is The Fastest Growing Health Threat To Americans
Anti-Alzheimer's, Antidimentia Tags: 120014-06-441100-52-1acetylcholineAlzheimers diseaseDonepezilMemantine Mar 12, 2013
Estimated Number of Cases of AD in the U.S. (millions). A report issued from the University of Washington in Seattle on March 5, 2013 revealed a startling statistic. The fastest growing health threat to Americans is not cancer or heart disease – it is Alzheimers disease! While this may not have been surprising information to[…]
Cases of Dementia and Alzheimer's Disease Rising, Memantine is a Viable Treatment
Antiparkinson Agent, Drug Research & Development API Tags: 41100-52-1Alzheimers diseaseDonepezilMemantine Jun 13, 2012
Memantine Hydrochloride, CAS number 41100-52-1, is an effective oral medication for treating patients with Alzheimer’s disease. LGM Pharma can provide the Memantine Hydrochloride TEVA API for compounding purposes in the US, and offers a full range of support and services to it’s clients. Memantine is the first in a new and formidable class of Alzheimer’s[…]